Prometheus Biosciences Catapults 176% On Promising Results In UC and Crohn's

Prometheus Biosciences (RXDX) reported promising results from two inflammatory disease studies on Wednesday, and RXDX stock catapulted by a triple-digit percentage.

The company studied its drug in patients with ulcerative colitis and Crohn's disease, two forms of inflammatory bowel disease.